Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · CERENOME, INC. (CNSY)

Cerenome files updated investor presentation with CNSide and REYOBIQ milestone details

Neutral Impact 2 of 5 other Written later

On September 30, 2026, Cerenome updated its corporate presentation for meetings with investors and analysts, and filed the updated slides as Exhibit 99.1 to a Form 8-K dated October 2, 2026. The filing contains no financial statements or guidance, so it gives shareholders operating metrics and milestone timelines rather than new financial results.

Key points

  • Filed under Item 8.01 (Other Events); presentation dated September 30, 2026 is Exhibit 99.1.
  • Presentation cites 24 commercial ordering institutions and 187 commercial CNSide TCE specimens in Q3 2026 through September 30, 2026, presented as actuals.
  • Medicare rate for CNSide expected effective January 1, 2027; Molecular Profile test launch planned for October 12, 2026.
  • The filing includes no financial statements or guidance; the presentation's forward-looking statements carry stated risks.

The filing

CompanyCERENOME, INC. (CNSY)
Form8-K, current report
Filed with the SECOct 2, 2026, 7:30 AM ET
Accession number0001193125-26-411259

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.